Venous Thromboembolism – Pipeline Review, Q1 2011
Venous Thromboembolism - Pipeline Review, Q1 2011
Reference Code: GMDHC261IDB
Publication Date: February 2011
Venous Thromboembolism – Pipeline Review, Q1 2011 GMDHC261IDB / Pub FEB 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
Page(1)
Venous Thromboembolism – Pipeline Review, Q1 2011
Ta b le o f Co n te n ts
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Venous Thromboembolism Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Venous Thromboembolism 9
Venous Thromboembolism Therapeutics under Development by Companies 11
Venous Thromboembolism Therapeutics under Investigation by Universities/Institutes 13
Companies Involved in Venous Thromboembolism Therapeutics Development 15
Bristol-Myers Squibb Company 15
Boehringer Ingelheim GmbH 15
Sanofi-Aventis 16
GlaxoSmithKline plc 16
Daiichi Sankyo Company, Ltd 17
Merck & Co., Inc. 17
Takeda Pharmaceutical Company Limited 18
Astellas Pharma Inc. 18
Bayer AG 19
ARYx Therapeutics 19
ThromboGenics NV 21
Italfarmaco S.p.A. 21
Regado Biosciences. 22
Transtech Pharma, Inc. 22
Eurofarma 23
Universities/Institutes Involved in Venous Thromboembolism Therapeutics Development 24
Venous Thromboembolism - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Late Stage Drug Profiles – Companies 30
Actiparin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Apixaban - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Apixaban - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Arixtra - Drug Profile 35
Product Description 35
Mechanism of Action 35
Venous Thromboembolism – Pipeline Review, Q1 2011 GMDHC261IDB / Pub FEB 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Venous Thromboembolism – Pipeline Review, Q1 2011
R&D Progress 35
AVE5026 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
BIBR 1048 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Edoxaban - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Edoxaban - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Heparin Sodium - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Heptar - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Idraparinux - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Nadroparin Calcium - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Sodium Heparin - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Tecarfarin - Drug Profile 46
Product Description